Business
Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug "XILIVE" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising
Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug "XILIVE" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug \"XILIVE\" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising\n \n \nEaston Pharmaceuticals Enters Into Cancer Drug Industry by Acquiring Initial Minority Ownership Interest in Experimental Cancer Drug \"XILIVE\" With 12 Month Option to Purchase Remaining Interest; Preliminary Feedback Extremely Promising\n \n BELLPORT, NY--(Marketwired - Nov 6, 2013) - Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products announced today It has purchased an initial 10 percent ownership interest in experimental cancer drug \"XILIVE\" From a private Canadian company and individual.\n Easton Pharmaceuticals 10 percent cash purchase of \"Xilive\", an early stage, experimental cancer drug was finalized after completing a conditional financing with an accredited non-affiliated investor with additional funds committed. The purchase agreement for \"Xilive\" provides the company with an exclusive option to purchase the remaining ownership interest, exercisable anytime over the next 12 month time period. \n Xilive is a drug that was developed 7 years ago and utilized under compassionate grounds on two individuals suffering from various forms of advanced stage cancer. The first individual, age 57, suffering from Lymphoma was administered \"Xilive\" simultaneously with chemotherapy and previously given a 50/50 chance of survival by physicians. The second individual, in his mid 60's, suffering from lung cancer was solely administered \"Xilive\" after being diagnosed and advised by physicians that the cancer was in its advanced stages where chemotherapy and surgery we're no longer considered a viable medical treatment option. Both individuals have thus far reached and past the critical 5 years or more time period after being diagnosed and advised that their cancers were in remission. One of the individuals suffering from advanced stage lymphoma has been diagnosed cancer free for more than 5 years. Both individuals continue to willingly use \"Xilive\" as a maintenance and preventative treatment. \n In Canada as well as in various states in the United St...